As the global opioid crisis drives prescribers, patients, payors and policymakers toward non-addictive alternatives, nonsteroidal anti-inflammatory drugs ("NSAIDs") are increasingly used to treat acute pain. However, today's NSAIDs can cause gastrointestinal ("GI") ulcers and bleeding, especially at the higher doses often employed in acute indications.

Positioned as the non-opioid of choice for acute pain, our lead drug, otenaproxesul, has demonstrated profound GI safety and robust efficacy in chronic pain in Phase IIB trials. In targeting the $25+ billion1 acute pain market, Antibe aims to address a broad range of acute pain indications, including post-operative pain, acute musculoskeletal pain, dysmenorrhea, migraine, gout and dental pain.

Further leveraging our platform, the next planned addition to our pipeline targets inflammatory bowel disease, a $16 billion2 market long in need of safer, more effective treatments.
Anti-Inflammatory Drug Platform
Antibe’s platform targets inflammation by harnessing the unique properties of hydrogen sulfide to improve the safety and potency of existing anti-inflammatory medicines. More than 20 years of academic and commercial research have uncovered hydrogen sulfide’s key role in a wide range of biological functions. These include the promotion of anti-oxidant responses, activation of anti-inflammatory genes and the unique ability to substitute for oxygen to produce cellular energy, underscoring its crucial role throughout biology.